Vermont releases drug pricing report

In its first report since the passage of a new price transparency law, the Vermont Attorney General's office identified drugs with substantial increases in wholesale acquisition cost (WAC). The document named three branded therapies -- EpiPen, Prevacid lansoprazole and Humira adalimumab -- with triple-digit percentage increases from 2012-16.

The report, produced in consultation with the Department of Vermont Health Access (DVHA) and the Green Mountain Care Board (GMCB), is required under legislation signed into law in June (see BioCentury Extra, June 3)...